Biogen
BIIB
Market cap $21.3B

146.47 USD

-0.92

0.62%

At close Dec 20, 4:00 PM EST

After hours

145.70

-0.77

0.53%

1 day

-0.62%

5 days

-1.70%

1 month

-6.11%

3 months

-26.53%

6 months

-35.07%

Year to date

-45.29%

1 year

-40.98%

5 years

-51.35%

10 years

-58.42%

About: Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva (oncology) and Ocrevus (multiple sclerosis) are marketed via a collaboration with Roche. Biogen markets several multiple sclerosis drugs including Plegridy, Tysabri, Tecfidera, and Vumerity. Biogen's newer products include Spinraza (SMA, with partner Ionis), Leqembi (Alzheimers, with partner Eisai), Skyclarys (Friedreich's Ataxia, Reata), Zurzuvae (postpartum depression, Sage), and Qalsody (ALS, Ionis). Biogen has several drug candidates in phase 3 trials in neurology, immunology, and rare diseases.

Employees: 7,570

Healthcare Biological Products, Except Diagnostic Substances

0

Funds holding %

of 6,809 funds

0

Analysts bullish %

of 16 analysts

Fund manager confidence

Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)

2.06% less ownership

Funds ownership: 89.29% [Q2] → 87.23% (-2.06%) [Q3]

3% less funds holding

Funds holding: 922 [Q2] → 891 (-31) [Q3]

19% less capital invested

Capital invested by funds: $30.1B [Q2] → $24.5B (-$5.65B) [Q3]

24% less first-time investments, than exits

New positions opened: 98 | Existing positions closed: 129

25% less call options, than puts

Call options by funds: $213M | Put options by funds: $282M

27% less funds holding in top 10

Funds holding in top 10: 11 [Q2] → 8 (-3) [Q3]

29% less repeat investments, than reductions

Existing positions increased: 261 | Existing positions reduced: 370

See Fund Rankings

Research analyst outlook

16 Wall Street Analysts provided 1 year price targets over the past 3 months

Low target

$164

12%

upside

Avg. target

$224

53%

upside

High target

$300

105%

upside

16 analyst ratings

6 positive

38%

10 neutral

63%

0 negative

0%

BMO Capital Evan Seigerman 50% 1-year accuracy 8 / 16 met price target	12%upside $164	Market Perform Downgraded	20 Dec 2024
B of A Securities Tim Anderson 50% 1-year accuracy 3 / 6 met price target	22%upside $178	Neutral Reinstated	10 Dec 2024
Jefferies Michael Yee 10% 1-year accuracy 1 / 10 met price target	23%upside $180	Hold Downgraded	9 Dec 2024
Mizuho Salim Syed 35% 1-year accuracy 7 / 20 met price target	41%upside $207	Outperform Maintained	21 Nov 2024
Needham Ami Fadia 37% 1-year accuracy 57 / 154 met price target	84%upside $270	Hold Downgraded	18 Nov 2024

See Analyst Rankings

Financial journalist opinion

Based on 8 articles about BIIB published over the past 30 days

Private Medicare plans must cover Biogen's ALS drug, US agency says

The Centers for Medicare & Medicaid Services has directed private insurers providing Medicare Advantage plans to cover Biogen's amyotrophic lateral sclerosis drug Qalsody after finding instances of coverage denial.

Private Medicare plans must cover Biogen's ALS drug, US agency says

Investors Business Daily

Analysts Predict These Will Be Next Year's Top 10 Stocks

Missed out on this year's top S&P 500 stocks? Analysts are already offering up their ideas on which stocks will rule in 2025.

Analysts Predict These Will Be Next Year's Top 10 Stocks

Zacks Investment Research

Biogen Stock Declines 21.4% in 3 Months: How to Play the Stock

Though there is uncertainty about Biogen's sales and profits improving significantly, investors can hold the stock given the potential of its new drugs.

Biogen Stock Declines 21.4% in 3 Months: How to Play the Stock

Biogen Downgraded On Pipeline Setbacks And Leqembi Sales Slowdown

Jefferies downgraded Biogen Inc BIIB, citing the company's tough setup.

Biogen Downgraded On Pipeline Setbacks And Leqembi Sales Slowdown

GeneDx to Expand Access to Exome Testing for Pediatric Epilepsy Patients with New Partners

STAMFORD, Conn.--(BUSINESS WIRE)--GeneDx today announced Biogen, Praxis Precision Medicines and Stoke Therapeutics as the founding partners to its Patient Access Program for epilepsy.

GeneDx to Expand Access to Exome Testing for Pediatric Epilepsy Patients with New Partners

Biogen Inc. (BIIB) Presents at 7th Annual Evercore ISI HealthCONx Healthcare Conference Call Transcript

Biogen Inc. (NASDAQ:BIIB ) 7th Annual Evercore ISI HealthCONx Healthcare Conference Call December 3, 2024 9:10 AM ET Company Participants Alisha Alaimo - President and Head of North America Michael McDonnell - Chief Financial Officer Conference Call Participants Umer Raffat - Evercore ISI Umer Raffat Okay, thank you guys for joining us. Pleasure to have Biogen Management.

Biogen Inc. (BIIB) Presents at 7th Annual Evercore ISI HealthCONx Healthcare Conference Call Transcript

Biogen expects steady growth for Alzheimer's drug Leqembi in near term

Biogen expects growth of its keenly watched Alzheimer's disease drug, Leqembi, to see a "linear trend" in the United States in the near term, a company executive said at a healthcare conference on Tuesday.

Biogen expects steady growth for Alzheimer's drug Leqembi in near term

The Motley Fool

These Are the 5 Worst-Performing Stocks in the Nasdaq-100 With 2024 Almost Over

The Nasdaq-100 index tracks the largest 100 non-financial companies on the Nasdaq stock exchange. Although it's not a part of the U.S. stock market's big three indexes ( S&P 500 , Nasdaq Composite, and Dow Jones), the Nasdaq-100 has grown in popularity over the years because of its concentration of tech stocks (almost 60%), many of which have seen their valuations skyrocket in recent years.

These Are the 5 Worst-Performing Stocks in the Nasdaq-100 With 2024 Almost Over

Biogen Gains Momentum With Positive Lupus Drug Results, Analyst Sees Modest Valuation Upside

On Tuesday, UCB SA UCBJY UCBJF and Biogen Inc. BIIB presented detailed results from the Phase 3 PHOENYCS GO study evaluating dapirolizumab pegol (DZP) for systemic lupus erythematosus.

Biogen Gains Momentum With Positive Lupus Drug Results, Analyst Sees Modest Valuation Upside

Dapirolizumab Pegol Phase 3 Data Presented at the American College of Rheumatology Shows Significant Reduction in Systemic Lupus Erythematosus Disease Activity

BRUSSELS, Belgium and CAMBRIDGE, Mass., Nov. 19, 2024 (GLOBE NEWSWIRE) -- UCB (Euronext Brussels: UCB) and Biogen Inc. (NASDAQ: BIIB) today presented detailed results from the Phase 3 PHOENYCS GO study evaluating dapirolizumab pegol (DZP), a novel Fc-free anti-CD40L drug candidate, demonstrating significant clinical improvement in disease activity in people living with moderate-to-severe systemic lupus erythematosus (SLE). The results were shared during an oral, late-breaker presentation at ACR Convergence 2024, the American College of Rheumatology's annual meeting, in Washington, DC.

Dapirolizumab Pegol Phase 3 Data Presented at the American College of Rheumatology Shows Significant Reduction in Systemic Lupus Erythematosus Disease Activity

See News Rankings

Charts implemented using Lightweight Charts™